T. Rowe Price Investment Management, Inc. Arcellx, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Arcellx, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 1,943,726 shares of ACLX stock, worth $166 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
1,943,726
Previous 1,665,138
16.73%
Holding current value
$166 Million
Previous $109 Million
17.18%
% of portfolio
0.08%
Previous 0.07%
Shares
8 transactions
Others Institutions Holding ACLX
# of Institutions
223Shares Held
49.1MCall Options Held
245KPut Options Held
885K-
Paradigm Biocapital Advisors LP New York, NY4.65MShares$398 Million14.29% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.94MShares$338 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$321 Million20.45% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$301 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.04MShares$260 Million4.37% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.75B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...